Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT69TQN)

• DTT Name: Integrin alpha-V/beta-3 (ITGAV/B3) DTT Info
• Gene Name: ITGAV-ITGB3

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilengitide	DMEAOZ0	Rheumatoid arthritis	FA20	Phase 3	[1]
ATN-161	DM4T9RS	Renal cell carcinoma	2C90	Phase 2	[2]
Fluciclatide F-18	DME01HT	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Intetumumab	DMBXEG9	Prostate cancer	2C82.0	Phase 2	[4]
VLTS-589	DM4O17U	Peripheral vascular disease	BD4Z	Phase 2	[5]
SF0166	DM4NK3J	Diabetic macular edema	9B71.02	Phase 1/2	[6]
AMEP	DMFELMQ	Melanoma	2C30	Phase 1	[7]

4 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitaxin	DMHCLVQ	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[8]
SB-267268	DMIBFAV	Osteoporosis	FB83.0	Discontinued in Phase 1	[9]
SB-273005	DMV7M1H	Osteoporosis	FB83.0	Discontinued in Phase 1	[10]
PS-388023	DM8P05S	Ocular disease	1F00.1Z	Terminated	[11]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
18F-SMIBR-K5	DM2VZMC	Solid tumour/cancer	2A00-2F9Z	Investigative	[12]
IS20I	DMXPMA6	Discovery agent	N.A.	Investigative	[13]

References

• [1] The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.PLoS One.2009;4(2):e4449.
• [2] A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
• [3] Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.J Nucl Med.2009 Jan;50(1):116-22.
• [4] A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52.
• [5] AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.
• [8] Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood. 2000 Jan 15;95(2):368-74.
• [9] SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.
• [10] Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthri... Arthritis Rheum. 2001 Jan;44(1):128-37.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin alphavbeta3 expression in vivo. Nucl Med Biol. 2013 Jul;40(5):710-6.
• [13] IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery. 2003 Jan;52(1):177-85; discussion 185-6.